Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway

Vascular Pharmacology

Volumn 56, Issue 1-2, 2012, Pages 1-8

  Sung, Jin Young ^a   Choi, Hyoung Chul ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

AMP activated protein kinase (AMPK); Nifedipine; Proliferation; Reactive oxygen species; Vascular smooth muscle cells (VSMCs)

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NIFEDIPINE; PROTEIN KINASE LKB1; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NIFEDIPINE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84856252486     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.06.001     Document Type: Article

References (31)

1. Choi H.C., Song P., Xie Z., Wu Y., Xu J., Zhang M., Dong Y., Wang S., Lau K., Zou M.H. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J. Biol. Chem. 2008, 283:20186-20197.
2. Clunn G.F., Sever P.S., Hughes A.D. Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int. J. Cardiol. 2010, 139:2-6.
3. Cominacini L., Fratta Pasini A., Garbin U., Pastorino A.M., Davoli A., Nava C., Campagnola M., Rossato P., Lo Cascio V. Antioxidant activity of different dihydropyridines. Biochem. Biophys. Res. Commun. 2003, 302:679-684.
4. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2000, 8:774-785.
5. Hardie D.G. The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci. 2004, 117:5479-5487.
6. Hawley S.A., Selbert M.A., Goldstein E.G., Edelman A.M., Carling D., Hardie D.G. 5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 1995, 270:27186-27191.
7. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., Hardie D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2:9-19.
8. Hirata A., Igarashi M., Yamaguchi H., Suwabe A., Daimon M., Kato T., Tominaga M. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br. J. Pharmacol. 2000, 131:1521-1530.
9. Hughes A.D. Calcium channels in vascular smooth muscle cells. J. Vasc. Res. 1995, 32:353-370.
10. 2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 2005, 280:29060-29066.
11. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T., Taguchi T., Nakamaru K., Yano M., Kukidome D., Matsumoto K., Toyonaga T., Asano T., Nishikawa T., Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ. Res. 2005, 97:837-844.
12. Inaba S., Iwai M., Tomono Y., Senba I., Furuno M., Kanno H., Okayama H., Mogi M., Higaki J., Horiuchi M. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am. J. Hypertens. 2009, 22:145-150.
13. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension 1992, 20:713-736.
14. Jackson C.L., Bush R.C., Bowyer D.E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 1989, 80:17-26.
15. Jin Z.G., Berk B.C. SOXF: redox mediators of vascular smooth muscle cell growth. Heart 2004, 90:488-490.
16. Kim J.E., Choi H.C. Losartan inhibits vascular smooth muscle cell proliferation through activation of AMP-activated protein kinase. Korean J. Physiol. Pharmacol. 2010, 14:299-304.
17. Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Mäkelä T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
18. 2+ signaling, genes and the cell cycle. Cell Calcium 2010, 48:243-250.
19. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 2006, 574:63-71.
20. Park J., Ha H., Seo J., Kim M.S., Kim H.J., Huh K.H., Park K., Kim Y.S. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am. J. Transplant. 2004, 4:1982-1990.
21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
22. Sakamoto K., Goransson O., Hardie D.G., Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E310-E317.
23. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
24. 2+ pool content is linked to control of cell growth. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4986-4990.
25. Skelding K.A., Rostas J.A., Verrills N.M. Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinase I and II. Cell Cycle 2011, 10:631-639.
26. Stepien O., Zhang Y., Zhu D., Marche P. Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J. Hypertens. 2002, 20:95-102.
27. Tsaousi A., Williams H., Lyon C.A., Taylor V., Swain A., Johnson J.L., George S.J. Wnt4/{beta}-catenin signaling induces VSMC proliferation and is associated with intimal thickening. J. Circ. Res. 2011, 108:427-436.
28. Wang S., Xu J., Song P., Viollet B., Zou M.H. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 2009, 58:1893-1901.
29. Wang M., Monticone R.E., Lakatta E.G. Arterial aging: a journey into subclinical arterial disease. Curr. Opin. Nephrol. Hypertens. 2010, 19:201-207.
30. Wu J.R., Liou S.F., Lin S.W., Chai C.Y., Dai Z.K., Liang J.C., Chen I.J., Yeh J.L. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol. Res. 2009, 59:48-56.
31. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.